To evaluate the long-term efficacy of two maintenance treatment patterns of secukinumab-the standard maintenance group and the non-standard maintenance group-by assessing the median time to onset and incidence of secondary failure, as well as the time to regain response after dose escalation of secukinumab (including re-initiation of intensive dosing or shortening of the injection interval) in patients who experienced secondary failure.
Age ≥ 18 years, with a clinical diagnosis of moderate-to-severe plaque psoriasis.
Initiated secukinumab treatment at our center between January 2020 and December 2025, and completed the standard 5-week induction period.
Achieved PASI 75 response at the end of the induction period.
Had a clearly defined maintenance treatment pattern (standard or non-standard), with complete treatment records and regular efficacy assessments.
Failure to complete the induction period, or failure to achieve PASI 75 response by the end of the induction period.
Irregular maintenance treatment pattern, or substantial missing data.
Use of other targeted biologic agents or small molecule drugs during the maintenance period.
Permanent discontinuation of treatment for non-efficacy reasons, such as pregnancy, severe infection, or malignancy.